OS Therapies (OSTX) Retained Earnings (2023 - 2026)
OS Therapies' (OSTX) quarterly Retained Earnings came in at -$77.6 million in Q1 2026, down 83.37% YoY from -$466.6 million in Q1 2025, and down 15.47% on a QoQ basis from -$67.2 million in Q4 2025.
OS Therapies (OSTX) Retained Earnings (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Retained Earnings data on file, last reported at -$77.6 million in Q1 2026.
- Quarterly Retained Earnings fell 83.37% year-over-year to -$77.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.6 million (down 83.37% YoY) and the FY2025 annual result came in at -$67.2 million, down 74.82% from the prior year.
- Retained Earnings declined to -$77.6 million in Q1 2026, from -$67.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $34.7 million in Q3 2024 to a low of -$77.6 million in Q1 2026.
- A 4-year average of -$34.9 million and a median of -$40.4 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings tumbled 799.36% — and 2025, when it slumped 36.44%.
- Tracing OSTX's Retained Earnings over 4 years: stood at $5.5 million in 2023, then sank by 799.36% to -$38.4 million in 2024, then tumbled by 74.82% to -$67.2 million in 2025, then slipped by 15.47% to -$77.6 million in 2026.
- The last three Retained Earnings figures came in at -$77.6 million (Q1 2026), -$67.2 million (Q4 2025), and -$53.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | OS Therapies | 19.56 Mn | 19.56 Mn | - | -86.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.58 Mn |
| Dec 31, 2025 | -67.19 Mn |
| Sep 30, 2025 | -53.73 Mn |
| Jun 30, 2025 | -46.85 Mn |
| Mar 31, 2025 | -42.31 Mn |
| Dec 31, 2024 | -38.43 Mn |
| Sep 30, 2024 | 34.71 Mn |
| Jun 30, 2024 | -32.57 Mn |
| Mar 31, 2024 | -31.01 Mn |
| Dec 31, 2023 | 5.50 Mn |